Superior Court Upholds $70M Risperdal Verdict
A Pennsylvania Superior Court has rejected Johnson & Johnson’s appeal of a 2016 $70 million verdict awarded to a 20 year-old Tennessee man, Andrew Yount (A.Y.) who developed gynecomastia after taking the antipsychotic drug Risperdal since he was 4-1/2 years old. Gynecomastia is an irreversible condition caused by an increase in the hormone prolactin and […]
New Trial for Risperdal Injury Previously Tossed
In another win for plaintiffs injured by Risperdal, a Pennsylvania appellate court reversed a trial courts decision to grant the defendants motion for nonsuit, mid-trial. This decision will send the case back to the Pennsylvania Courts of Common Pleas for retrial. In the 2016 case of T.M. vs Janssen Pharmaceuticals, the trial judge decided mid-trial […]
Judge Proceeds with Risperdal Punitive Damages Trial
Philadelphia Court of Common Pleas Judge Arnold L. New has ordered two Risperdal cases to proceed in a new trial for punitive damages. In both cases, causation and compensatory damage were already awarded the plaintiffs– Stange v. Janssen Pharmaceuticals ($500,000) and Murray v. Janssen Pharmaceuticals ($1.75M later reduced to $680,000). Judge New previously ruled in agreement […]
Judge Urges Appeals Court to Uphold $70M Risperdal Verdict
Philadelphia Court of Common Pleas Judge Paula Patrick urges the Pennsylvania Superior Court to uphold the $70 Million jury verdict in A.Y. v. Janssen Pharmaceuticals. AY is one of many boys who developed gynecomastia after taking Janssen’s anti-psychotic medication Risperdal. This is the 5th trial for Risperdal, with over 6,000 awaiting trial in a consolidated […]
Sheller Risperdal settlements front page Legal Intelligencer
2012-10-05 The first trial in which evidence was taken in the mass tort litigation over Risperdal, the antipsychotic drug that plaintiffs have claimed causes males to grow breasts, was settled as part of a group of five cases that resolved this week for undisclosed amounts, according to the plaintiffs’ lawyers and a statement from the […]
